Theravance Biopharma, Inc. Business Finance Contracts & Agreements
24 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Indenture Agreements (3)
- Note Agreements (2)
- Purchase Agreements (2)
- Registration Rights Agreements (3)
- Release Agreements (2)
- Share Agreements (5)
- Underwriting Agreements (5)
- Release Agreement, dated as of July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC, Royalty Pharma Investments 2019 ICAV, Theravance Respiratory Company, LLC,... (Filed With SEC on July 14, 2022)
- Equity Purchase and Funding Agreement, dated as of July 13, 2022, by and between Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV (Filed With SEC on July 14, 2022)
- Underwriting Agreement among Theravance Biopharma, SVB Leerink LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters,... (Filed With SEC on June 28, 2021)
- Waiver and Assignment of Registration Rights and Voting Agreement among GSK Finance (No.3) plc, Glaxo Group Limited and Theravance Biopharma, Inc. dated as of June 22, 2020 (Filed With SEC on June 25, 2020)
- Registration Rights Agreement among Theravance Biopharma, Inc., GSK Finance (No.3) plc and GlaxoSmithKline plc dated June 22, 2020 (Filed With SEC on June 25, 2020)
- First Amendment of Registration Rights Agreement with Glaxo Group Limited (Filed With SEC on May 8, 2020)
- Form of Note Purchase Agreement, dated February 21, 2020 by and among Theravance Biopharma R&D, Inc., Triple Royalty Sub II LLC, and the Purchasers (Filed With SEC on February 27, 2020)
- Underwriting Agreement among Theravance Biopharma, Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters,... (Filed With SEC on February 13, 2020)
- Agreement and General Release between Theravance Biopharma US, Inc. and Shehnaaz Suliman, dated March 1, 2019 (Filed With SEC on May 10, 2019)
- Form of Note Purchase Agreement, dated November 30, 2018 (Filed With SEC on December 3, 2018)
- Asset Purchase Agreement, dated as of November 1, 2018, by and among Cumberland Pharmaceuticals Inc. on the one hand, and Theravance Biopharma Ireland Limited and Theravance... (Filed With SEC on November 16, 2018)
- THERAVANCE BIOPHARMA, INC. 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 FIRST SUPPLEMENTAL INDENTURE DATED AS OF NOVEMBER 2, 2016 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE (Filed With SEC on November 2, 2016)
- THERAVANCE BIOPHARMA, INC. 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 FIRST SUPPLEMENTAL INDENTURE DATED AS OF NOVEMBER 2, 2016 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE (Filed With SEC on November 2, 2016)
- THERAVANCE BIOPHARMA, INC. as Issuer and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Trustee Indenture Dated as of November 2, 2016 (Filed With SEC on November 2, 2016)
- THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) $200,000,000 3.250% Convertible Senior Notes due 2023 UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)
- THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 3,850,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)
- THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT March 14, 2016 (Filed With SEC on May 10, 2016)
- THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 4,765,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on May 2, 2016)
- Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan (the Plan) UK Addendum (Filed With SEC on March 11, 2016)
- THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT October 26, 2015 (Filed With SEC on October 26, 2015)
- THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT October 7, 2015 (Filed With SEC on October 13, 2015)
- THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT January 30, 2015 (Filed With SEC on April 24, 2015)
- CONSENT TO ASSIGNMENT (Filed With SEC on August 14, 2014)
- CONSENT TO ASSIGNMENT (Filed With SEC on August 14, 2014)
